Form 8-K · Current Report · Filed 2025-10-28
Zoetis Appoints Stephanie Tilenius to its Board of Directors
Zoetis Inc. announced on October 28, 2025, the appointment of Stephanie Tilenius to its Board of Directors, effective December 1, 2025. Tilenius, a serial entrepreneur with extensive experience in digital health and AI, will bring strategic insights as the company advances its digital transformation. The appointment increases the Board size from 12 to 13 members. A press release detailing the appointment was issued as part of Regulation FD Disclosure. The company also provided financial exhibit details as part of the filing.
- Filer
- Zoetis Inc. ZTS · NYSE
- Filed
- Accession
- 0001555280-25-000266
- CIK
- 0001555280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$147.53
Next session
-2.4%
Since filing
-47.6%
Latest close
$77.29
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ZTS reporting the same item, with the next session's move:
Exhibits (1)
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Never miss another ZTS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.